Paul Tudor Jones's TBPH Position Overview
Paul Tudor Jones (via Tudor Investment Corp Et Al) currently holds 120,122 shares of Theravance Biopharma, Inc. (TBPH) worth $1.95 M, representing 0.00% of the portfolio. First purchased in 2015-Q2, this long-term strategic position has been held for 21 quarters.
Based on 13F filings, Paul Tudor Jones has maintained a strategic position in TBPH, demonstrating sustained confidence in this investment. Largest addition occurred in Q1 2024, adding 167,529 shares. Largest reduction occurred in Q3 2025, reducing 145,515 shares.
Analysis based on 13F filings available since 2013 Q2
Paul Tudor Jones's Theravance Biopharma (TBPH) Holding Value Over Time
Track share changes against reported price movement
Quarterly Theravance Biopharma (TBPH) Trades by Paul Tudor Jones
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | -70,007 | Reduce 36.82% | 120,122 | $16.23 |
| Q4 2025 | +139,081 | Add 272.45% | 190,129 | $18.71 |
| Q3 2025 | -145,515 | Reduce 74.03% | 51,048 | $14.60 |
| Q2 2025 | -10 | Reduce 0.01% | 196,563 | $11.03 |
| Q1 2025 | -5 | Reduce 0.00% | 196,573 | $8.93 |
| Q3 2024 | +2,810 | Add 1.45% | 196,578 | $8.06 |
| Q2 2024 | +16,156 | Add 9.10% | 193,768 | $8.48 |
| Q1 2024 | +167,529 | Add 1661.50% | 177,612 | $8.97 |
| Q4 2023 | -97,665 | Reduce 90.64% | 10,083 | $11.24 |
| Q3 2023 | -13,918 | Reduce 11.44% | 107,748 | $8.63 |
| Q2 2023 | +13,031 | Add 12.00% | 121,666 | $10.35 |
| Q1 2023 | +15,201 | Add 16.27% | 108,635 | $0.01 |
| Q4 2022 | +93,434 | New Buy | 93,434 | $0.01 |
| Q3 2022 | -103,280 | Sold Out | 0 | $0.00 |
| Q2 2022 | +71,364 | Add 223.60% | 103,280 | $9.06 |
| Q1 2022 | -141,498 | Reduce 81.60% | 31,916 | $9.56 |
| Q4 2021 | +121,705 | Add 235.37% | 173,414 | $11.05 |
| Q3 2021 | +51,709 | New Buy | 51,709 | $7.41 |
| Q3 2015 | -27,800 | Sold Out | 0 | $0.00 |
| Q2 2015 | +27,800 | New Buy | 27,800 | $13.02 |
Paul Tudor Jones's Theravance Biopharma Investment FAQs
Paul Tudor Jones first purchased Theravance Biopharma, Inc. (TBPH) in Q2 2015, acquiring 27,800 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Paul Tudor Jones has held Theravance Biopharma, Inc. (TBPH) for 21 quarters since Q2 2015.
Paul Tudor Jones's largest addition to Theravance Biopharma, Inc. (TBPH) was in Q1 2024, adding 177,612 shares worth $1.59 M.
According to the latest 13F filing for Q1 2026, Paul Tudor Jones's firm, Tudor Investment Corp Et Al, owns 120,122 shares of Theravance Biopharma, Inc. (TBPH), valued at approximately $1.95 M.
As of the Q1 2026 filing, Theravance Biopharma, Inc. (TBPH) represents approximately 0.00% of Paul Tudor Jones's publicly disclosed stock portfolio, making it one of their key holdings.
Paul Tudor Jones's peak holding in Theravance Biopharma, Inc. (TBPH) was 196,578 shares, as reported at the end of Q3 2024.